Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

Roche in Pact with Biocryst

December 5, 2005 | A version of this story appeared in Volume 83, Issue 49

Roche and BioCryst Pharmaceuticals will collaborate on BioCryst's Phase I compound BCX-4208, being developed for the prevention of transplantation rejection and autoimmune diseases. Roche will obtain worldwide rights to the drug in exchange for a $25 million up-front payment and $5 million for supplies of the drug. Future payments could reach $530 million. BioCryst licensed the compound from Albert Einstein College of Medicine and Industrial Research Ltd.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.